Endovascular splinting devices and methods
A method for placing a splint assembly transverse a heart chamber includes providing an elongate member having a first end and a second end and a deployable heart-engaging assembly connected to at least the first end. The method includes advancing the elongate member through vasculature structure and into the heart chamber such that the first end of the elongate member extends through a first location of a wall surrounding the heart chamber and the second end extends through a second location of the heart chamber wall substantially opposite the first location. A deployable heart-engaging assembly is deployed such that it engages with a first exterior surface portion of the heart chamber wall adjacent the first location. The elongate member is secured with respect to the heart with a second heart-engaging assembly connected to the second end. The second heart-engaging assembly engages with a second exterior surface portion of the heart chamber wall adjacent the second location. A splint assembly includes an expandable heart-engaging assembly formed partially from portions forming the elongate member of the splint assembly. A delivery tool includes a tubular member configured to be advanced through vasculature structure and has a curved distal end.
Latest Patents:
The present invention pertains to devices for treating a failing heart and related methods for placing the devices. In particular, the invention pertains to splinting devices placed on the heart to reduce the radius of curvature and/or alter the geometry or shape of the heart to thereby reduce wall stress in the heart and improve the heart's pumping performance. The devices and methods of the present invention are directed toward endovascular techniques used to facilitate placement of the splinting devices on the heart.
BACKGROUND OF THE INVENTIONHeart failure is a common outcome in the progression of many forms of heart disease. Heart failure may be considered as the condition in which an abnormality of cardiac function is responsible for the inability of the heart to pump blood at a rate commensurate with the requirements of the metabolizing tissues, or can do so only at an abnormally elevated filling pressure. There are many specific disease processes that can lead to heart failure. Typically these processes result in dilatation of the left ventricular chamber. Etiologies that can lead to this form of failure include idiopathic, valvular, viral, and ischemic cardiomyopathies, including ventricular aneurysms.
The process of ventricular dilatation is generally the result of chronic volume overload or specific damage to the myocardium. In a normal heart that is exposed to long term increased cardiac output requirements, for example, that of an athlete, there is, an adaptive process of slight ventricular dilation and muscle myocyte hypertrophy. In this way, the heart fully compensates for the increased cardiac output requirements. With damage to the myocardium or chronic volume overload, however, there are increased ill requirements put on the contracting myocardium to such a level that this compensated state is never achieved and the heart continues to dilate.
One problem with a large dilated left ventricle is that there is a significant increase in wall tension and/or stress both during diastolic filling and during systolic contraction. In a normal heart, the adaptation of muscle hypertrophy (thickening) and ventricular dilatation maintain a fairly constant wall tension for systolic contraction. However, in a failing heart, the ongoing dilatation is greater than the hypertrophy and the result is a rising wall tension requirement for systolic contraction. This is felt to be an ongoing insult, to the muscle myocyte resulting in further muscle damage. The increase in wall stress also occurs during diastolic filling. Additionally, because of the lack of cardiac output, a rise in ventricular filling pressure generally results from several physiologic mechanisms. Moreover, in diastole there is both a diameter increase and a pressure increase over normal, both contributing to higher wall stress levels. The increase in diastolic wall stress is felt to be the primary contributor to ongoing dilatation of the chamber.
Mitral regurgitation is a condition whereby blood leaks through the mitral valve due to an improper positioning of the valve structures that causes the valve not to close entirely. Geometric abnormalities resulting from a dilated left ventricle may cause or exacerbate improper functioning of the mitral valve, including mitral valve regurgitation, i by altering the normal position and dimension of the valve, particularly the valve annulus.
Prior treatments for heart failure associated with such dilatation fall into three general categories. The first being pharmacological, for example, diuretics and ACE inhibitors. The second being assist systems, for example, pumps. Finally, surgical treatments also have been experimented with.
With respect to pharmacological treatments, diuretics have been used to reduce the workload of the heart by reducing blood volume and preload. Diuretics typically reduce extra cellular fluid which builds in congestive heart failure patients increasing preload conditions. Nitrates, arteriolar vasodilators, angiotensin converting enzyme (ACE) inhibitors have been used to treat heart failure through the reduction of cardiac workload by reducing afterload. Inotropes function to increase cardiac output by increasing the force and speed of cardiac muscle contraction. These drug therapies offer some beneficial effects but do not stop the progression of the disease.
Assist devices include mechanical pumps. Mechanical pumps reduce the load on the heart by performing all or part of the pumping function normally done by the heart. Currently, mechanical pumps are used to sustain the patient while a donor heart for transplantation becomes available for the patient.
There are at least four surgical procedures for treatment of heart failure associated with dilatation: 1) heart transplantation; 2) dynamic cardiomyoplasty; and 3) the Batista partial left ventriculectomy, and 4) the Jatene and Dor procedures for ischemic cardiomyopathy. These procedures are set forth in slightly more detail in U.S. application Ser. No. 09/532,049, filed Mar. 21, 2000, entitled “Splint Assembly for Improving Cardiac Function in Hearts, and Method for Implanting the Splint Assembly,” the entire disclosure of which is hereby incorporated by reference herein. Hereinafter, this application will be referred to as “the '049 application.”
SUMMARY OF THE INVENTIONDue to the drawbacks and limitations of the previous devices and techniques for treating a failing heart, including such a heart having dilated, infarcted, and/or aneurysmal tissue, there exists a need for alternative methods and devices that are less invasive and pose less risk to the patient, both after and during placement, and are likely to possess more clinical utility.
Thus, a more recent procedure for treating the various forms of heart failure discussed above includes placing devices on the heart to reduce the radius of curvature of the heart and/or alter the cross-sectional shape of the heart to reduce wall stress. The devices are configured to reduce the tension in the heart wall, and thereby reverse, stop or slow the disease process of a failing heart as it reduces the energy consumption of the failing heart, decreases isovolumetric contraction, increases isotonic contraction (sarcomere shortening), which in turn increases stroke volume. The devices reduce wall tension by changing. chamber geometry or shape and/or changing the radius of curvature or cross-section of a heart chamber. These changes may occur during the entire cardiac cycle or during only a portion of the cardiac cycle. The devices of the present invention which reduce heart wall stress in this way can be referred to generally as “splints.” These splints can be in the form of external devices, as described in U.S. application Ser. No. 09/157,486, filed Sep. 21, 1998, entitled “External Stress Reduction Device and Method,” the entire disclosure of which is incorporated by reference herein, or in the form of transventricular elongate tension members with heart-engaging assemblies, typically in the form of anchor pads, disposed on each end configured to engage substantially opposite portions of the chamber wall, embodiments of which are disclosed in the '049 application incorporated above.
An aspect of the present invention pertains to splint devices, and related splinting methods, for endovascular implantation on the heart. The splints of the present invention may be implanted endovascularly through remote vascular access sites. The inventive techniques and devices thus are minimally invasive and less risky to patients.
The advantages and purpose of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The advantages and purpose of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.
According to an aspect of the invention, a method for placing a splint assembly transverse a heart chamber comprises providing an elongate member having a first end and a second end and a deployable heart-engaging assembly connected to at least the first end. The method further includes advancing the elongate member through vasculature structure and into the heart chamber such that the first end of the elongate member extends through a first location of a wall surrounding the heart chamber and the second end extends through a second location of the heart chamber wall substantially opposite the first location. A deployable heart-engaging assembly is deployed such that it engages with a first exterior surface portion of the heart chamber wall adjacent the first location. The elongate member is secured with respect to the heart with a second heart-engaging assembly connected to the second end. The second heart-engaging assembly engages with a second exterior-surface portion of the heart chamber wall adjacent the second location.
Another aspect of the invention includes a splint assembly for treating a heart, comprising an elongate member configured to extend transverse a chamber of the heart and at least one heart-engaging assembly formed at least partially from portions forming the elongate member. The heart-engaging assembly has a collapsed configuration adapted to travel through a heart wall and an expanded configuration adapted to engage the heart wall.
Yet another aspect of the invention includes a delivery tool for delivering a transventricular splint assembly to a chamber of the heart, comprising a tubular member having a distal end and a proximal end, the distal end having a curved configuration and the tube defining a lumen configured to carry at least a portion of the splint assembly. The delivery tool further includes at least one support mechanism disposed proximate the distal end of the tubular member, the support mechanism being configured to stabilize the tubular member with respect to a heart wall surrounding the chamber. The tubular member is configured to be advanced through vasculature structure and into the heart chamber.
BRIEF DESCRIPTION OF THE DRAWINGSThe accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments of the invention and together with the description, serve to explain the principles of the invention. In the drawings,
The various aspects of the invention to be discussed herein generally pertain to devices and methods for treating heart conditions, including, for example, dilatation, valve incompetencies, including mitral valve leakage, and other similar heart failure conditions. Each device of the present invention preferably operates passively in that, once placed in the heart, it does not require an active stimulus, either mechanical, electrical, or otherwise, to function. Implanting one or more of these devices alters the shape or geometry of the heart, both locally and globally, and thereby increases the heart's efficiency. That is, the heart experiences an increased pumping efficiency through an alteration in its shape or geometry and concomitant reduction in stress on the heart walls. In addition, the devices of the present invention may operate to assist in the apposition of heart valve leaflets to improve valve function.
The inventive devices and related methods offer numerous advantages over the existing treatments for various heart conditions, including valve, incompetencies. The devices are relatively easy to manufacture and use, and the surgical techniques and tools for implanting the devices of the present invention do not require the invasive procedures of current surgical techniques. For instance, the endovascular techniques which will be described do not require performing a sternotomy or removing portions of the heart tissue, nor do they require opening the heart chamber or stopping the heart during operation. Such percutaneous insertion permits the splinting procedures to be performed in a wide variety of laboratories in the hospital. For these reasons, the techniques for implanting the devices of the present invention also are less risky to the patient, both during and after the implantation, and may be performed more quickly than other techniques. For instance, the procedures of the invention cause less pain to patients and permit quicker healing. In addition, certain endovascular splinting techniques to be described may limit bleeding at access sites, allowing relatively large catheters, cannula, and other similar implantation tools to be inserted in a percutaneous manner.
The disclosed inventive devices and related methods involve geometric reshaping of the heart. In certain aspects of the inventive devices and related methods, substantially the entire chamber geometry is altered to return the heart to a more normal state of stress. Models of this geometric reshaping, which includes a reduction in radius of curvature of the chamber walls, can be found in U.S. Pat. No. 5,961,440, issued Oct. 5, 1999, entitled “Heart Wall Tension Reduction Apparatus and Method,” and incorporated by reference herein. Prior to reshaping the chamber geometry, the heart walls experience high stress due to a combination of both the relatively large increased diameter of the chamber and the thinning of the chamber wall. Filling pressures and systolic pressures are typically high as well, further increasing wall stress. Geometric reshaping according to the present invention reduces the stress in the walls of the heart chamber to increase the heart's pumping efficiency, as well as to stop further dilatation of the heart.
It also is contemplated that the inventive endovascular splinting devices and methods will be used to support an infarcted heart wall to prevent further dilatation, or to treat aneurysms in the heart. U.S. application Ser. No. 09/422,328, filed on Oct. 21, 1999, entitled “Methods and Devices for Improving Cardiac Function in Hearts,” which is assigned to the same assignee as the present application and is incorporated by reference herein, discusses this form of heart failure in more detail. Moreover, it is contemplated that the devices and methods of using and implanting the devices could be used to treat heart valves, for example to aid in apposition of the leaflets of a mitral valve or modify the shape of the mitral valve, as described in U.S. application Ser. No. ______, to Richard F. Schroeder et al., filed on the same day as this application, assigned to the same assignee as the present application, and entitled “Methods and Devices for Improving Mitral Valve Function,” and incorporated by reference herein. One of ordinary skill in the art would understand that the use of the devices and methods described herein also could be employed in other chambers and for other valves associated with those chambers. For example, the devices and methods of the invention might be used to reduce stress in the left atrium to treat atrial fibrillation. The left ventricle has been selected for illustrative purposes because a large number of the disorders that the present invention treats occur in the left ventricle.
Reference will now be made in detail to the present preferred embodiments of the invention, examples of which are illustrated in the accompanying drawings. Wherever possible, the same reference numbers will be used throughout the drawings to refer to the same or like parts.
An embodiment of an endovascular splinting technique according to the present invention is shown in
Second, delivery through the right ventricle allows for straightforward positioning of the splints on the ventricular septal wall SW. Such positioning on the septal wall is preferable because it results in good left ventricle bisection, in a manner believed to have minimal negative impact on mitral valve function, and in some instances, a positive impact on mitral valve function and performance. Moreover, delivery through the right ventricle does not involve the free wall of the right ventricle and also does not restrict outflow of the blood from the heart.
According to the right ventricle delivery technique shown in
Additionally, as shown best in
Once catheter 100 is manipulated to a desired position on the ventricular septum SW, the support wire 106 is advanced to stabilize the tip position, as shown in
Once needle 105 is across the left ventricle chamber, its position is confirmed by TEE, X-Ray, or other visualization techniques, to assure good bisection and avoidance of key mitral valve and other heart structure. Conventional angiography utilizing a “pigtail” catheter. i.e., a dye injection catheter with a loop shape at the distal end, in the left ventricle LV and angiography catheters in one or both coronary artery ostia may also be used to aid in proper positioning of the associated delivery devices in the LV. It also is important to assure that needle 105 will not penetrate or damage any significant coronary vasculature. To assure this, an angiogram may be performed. Preferably the angiographic image is aligned to a position that looks down the axis of the needle in the portion of the needle which traverses the left ventricle LV. This angle will limit parallax to ensure that if the tip of the needle is not coincident with a significant vessel it will not pierce such vessel. Any small variation in the position of the needle tip can be adjusted by gentle manipulation of the delivery catheter.
As mentioned above, preferably needle 105 has soft threads 107 disposed on the surface of a tip portion of the needle, as shown in
Next, delivery catheter 100 is straightened and advanced over needle 105 into left ventricle LV. A tapered tip 101 on delivery catheter 100 enables catheter 100 to penetrate the septal and free walls SW, HW. Once distal anchoring balloon 103 traverses across the free wall HW, both balloons 102 and 103 are inflated, as shown in
As delivery catheter 100 is advanced over the distal end of needle 105, flexible threads 107 become collapsed and needle 105 can be removed from catheter 100. After removing needle 105, an elongate tension member 200 with a heart-engaging assembly, preferably in the form of a collapsible fixed anchor mechanism 201 (free wall anchor), on its distal end can be inserted into the lumen of catheter 100. Tension member 200 is advanced until it begins to emerge from the tip portion 101 of delivery catheter 100, as shown in
In this configuration, flexible elastic ring 203 can be easily deformed into a flattened hoop, without bundles 210 inhibiting this deformation. This is the configuration that tension member 200 has as it is advanced through the lumen of delivery catheter 100. To allow tension member 200 to be pushed through catheter 100, a stiffening mandrel may be disposed either inside or adjacent the braided portion of the tension member.
As shown in
After removing delivery catheter 100, a second heart-engaging assembly, preferably in the form of an adjustable anchor pad 205 (septal wall anchor) is advanced over tension member 200 using a deployment tool 209, as shown in
Adjustable pad 205 is advanced using deployment tool 209 over tension member 200 in essentially a “monorail” fashion, allowing anchor pad 205 to be oriented substantially adjacent and parallel to tension member 200 as tension member 200 slides through throughhole 205′. Once located at the septal wall SW, a tightening device 206, preferably in the form of a tube, is advanced over the outside of the tension member until the distal end of the tightening device 206 engages the adjustable pad 205. Manipulation of the tightening device 206 relative to tension member 200 positions adjustable pad 205 and tension member 200 into a position so as to alter the shape of the left ventricle LV.
Once a desired amount of shape change is achieved, adjustable pad 205 is deployed by manipulation of the deployment tool 209, in a manner similar to the technique disclosed in the '049 application. That is, the deployment tool 209 includes an actuator wire that is pre-engaged with an engagement collar (not shown) in adjustable pad assembly 205 such that when the actuator wire is pulled, the engagement collar travels through various channels disposed within the adjustable anchor pad 205. The engagement collar causes securement members, preferably in the form of pins or staples, such as staple 218 shown in
In another embodiment of the invention, splints can be positioned across the left ventricle via an endovascular route leading directly into the left ventricle rather than through the right ventricle. Using this approach, preferably the access site is located in one of the femoral arteries, in a manner similar to many cardiology procedures, for example. Although this route requires advancing delivery tools retrograde across the aortic valve, this delivery route permits the delivery catheter to be placed in approximately the middle of, rather than outside, the left ventricle, thus yielding a more symmetrical approach. The ability to position the splint to achieve a good bisection of the left ventricle therefore may be enhanced since the bisection may be easier to visualize prior to implanting the splints. Furthermore, it may be possible to stabilize the delivery system using walls on both sides of the left ventricle, thus requiring fewer additional support mechanisms.
The direct left ventricle delivery approach uses a guide device, preferably in the form of a delivery catheter, of a different structure than that used in the right ventricle delivery approach. As shown in
Once the distal tip of main catheter 301 resides in the left ventricle LV, curved catheters 302, 303 are advanced with their respective distal anchoring balloons 304, 305 inflated. Distal balloons 304, 305 serve to act as protective bumpers on the curved catheters so as to avoid damaging various heart structures as the catheters traverse the ventricle. The curvature of catheters 302, 303 causes the tips of the catheters to deflect laterally until the distal balloons 304, 305 of each catheter 302, 303 contact the inside surface of the left ventricle LV, at the septal wall SW and free wall HW, respectively. Once positioned, the curved catheters press against each other to form a self-supporting structure which remains in place during the beating of the heart. Once distal balloons 304, 305 contact the walls, sharpened wires 306, 307, similar to the one described above in the right ventricle delivery method and shown in detail in
Curved catheters 302, 303 then are advanced with both anchor balloons deflated over wires 306, 307, similar to the step described above in the right ventricle approach. After catheters 302, 303 have been advanced across the ventricular walls SW, HW at the appropriate positions, both balloons on each of curved catheters 302, 303 are inflated to keep the catheters securely positioned and stabilized with respect to the chamber walls, as shown in
A tension member 200, with a first heart-engaging assembly, preferably in the form of a deployable fixed anchor pad mechanism 201 (free wall anchor), on its distal end, similar to the tension member and deployable fixed pad mechanism discussed with respect to the right ventricle delivery method, is inserted into curved catheter 303 engaging the free wall HW, as shown in
At this point, tension member 200 is in a configuration similar to that shown in
In
After tip portion 400′ of delivery catheter 300 is positioned and oriented in the desired location with respect to septal wall SW, a hollow sharpened metallic guidewire, or needle, 402 is advanced through a central lumen 422 of delivery catheter 400, across the ventricular septum SW, and across the left ventricular chamber LV to free wall HW, as shown in
Hollow guidewire 402 has a sharpened tip 402′ and defines a central lumen plugged near tip 402′. The material used to make guidewire 402 preferably includes a superelastic nickel titanium alloy, or other similar like material. Two elastomeric balloons, a distal balloon 403 and a proximal balloon 404, are secured near the distal end of guidewire 402 slightly proximal to sharpened tip 402′. Distal balloon 403 is in flow communication with central lumen 422 of guidewire 402. Proximal balloon 404 is in fluid communication with an additional tube (not shown) positioned inside hollow guidewire 402. In this manner, each balloon 403, 404 can be independently inflated and deflated as required.
Balloons 403, 404 preferably are in a deflated condition as they are advanced across septal wall SW and then are inflated during advancement across the left ventricle LV. Inflating the balloons during advancement across the left ventricle LV may assist in visualizing the advancement path of the guidewire. To assist in such visualization, preferably the balloons are inflated with a radiographic contrast agent. The ability to visualize the advancement path of guidewire 402 may prevent damage to various cardiac structure as well as assist in ensuring proper positioning of the guidewire on the free wall HW.
As guidewire tip 402′ approaches free wall HW, distal balloon 403 is deflated, as shown in
Proximal balloon 404 is then deflated, as shown in
Aside from the configurations described above with reference to
Elongate tension member 500 preferably is similar to that described above in connection with the right ventricle delivery method and comprises a braid of high strength polymer fibers, preferably Spectra or other suitable like ultra-high molecular weight polyethylene. Tension member 500 may also include a covering along its full length made of a thin expanded polytetrafluoroethylene. Alternatively, only the region of tension member 500 which is disposed inside the ventricular chamber could include a covering.
Tension member 500 is thus advanced into position by sliding splint advancement catheter 406 carrying tension member 500 and anchor 502 over guidewire 402. That is, guidewire 402 will be placed within lumen 509 of anchor 502 and then within lumen 406′ of the catheter 406. The lumen 406′ and the lumen 509 will move relative to guidewire 402 to advance catheter 406, tension member 500, and anchor 502 in the configuration shown in
At this point in the splint delivery technique of
In the case where the proximal anchor is slidable on the tension member, a one way “ratchet” or friction surface may be disposed on the inner surface of the tubular portion of the anchor to prevent its displacement in one direction. For example, as shown in
A tightening device such as that described and shown in
In the alternative case where proximal anchor is pre-attached at a specified distance from the distal anchor, the left ventricle should be deformed prior to the pad deployment. The delivery catheter can act as a temporary proximal anchor, while the tension member and distal anchor are pulled proximally. Once the proper shape change of the left ventricle is attained, the proximal anchor may be deployed upon further retraction of the sheath of the splint advancement catheter. In this embodiment, preferably the distance between the distal and proximal anchors will be selected prior to delivery such that a desired shape change of the heart chamber may be obtained, since the adjustability of the shape change will be limited by the fixed position of the proximal anchor on the tension member. The delivery catheter may then be removed and excess tension member severed, again as described with reference to
While the splint delivery methods and devices just described in connection with
Other embodiments of a deployable, fixed heart-engaging assembly, or anchor, also are contemplated as within the scope of the present invention and are shown in
This expandable property of a braid can be utilized in the formation of yet another alternative deployable anchor structure.
For example,
In this embodiment, wire 345, particularly in the spiral region, preferably will remain together with the braid of tension member 340 even after diametric expansion in order provide the anchoring rigidity needed to secure the splint in place on the heart. Initially, the spiral portion of wire 345 may carry a significant portion of the load of anchor 342. However, it is anticipated that over time, the expanded braid forming anchor 342 would become ingrown with scar tissue, and therefore a relatively large portion of the chronic mechanical loading may be carried by the filaments of the braid. Using filaments of ultra-high molecular weight polyethylene has been shown to produce a tension member and anchor having high strength and high fatigue resistance. A portion of the wire that does not form the spiral may be removed, for example by torquing the wire and breaking it at a location slightly proximal to the spiral.
To prevent any of the braided portion distal of the expanded region from “creeping” back over the spiral region, the distal most region of the braid preferably is either fused or banded. This will prevent expansibility in those regions. Alternatively, those regions of the braided tension member could be woven with a higher pick count.
An alternative device for causing expansion of an expandable braid portion of a tension member 540 includes an inflatable balloon disposed inside braided tension member at the expandable portion forming the anchor, as shown in
One of ordinary skill in the art would recognize that the alternative distal anchors described above could be utilized in conjunction with any of the delivery techniques of the present invention and could be used as either the free wall anchor or septal wall anchor with modifications as necessary.
Another alternative embodiment for an expandable anchor would utilize an anchor similar to the expandable tab anchor described above with reference to
An alternative proximal anchor also may utilize the expandable capability of a relatively low pick count braid, in a manner similar to that described above for the distal, or free wall, anchor. In this embodiment, the entire braid of the tension member preferably includes the relatively low pick count permitting diametric expansion. The tension member and distal anchor could be delivered using any of the approaches described herein, but preferably one of the right ventricle approach methods. After the distal, or free wall, anchor is delivered, the proper ventricle shape change can be induced using a tightening device in the form of a simple tube, such as the one described above, but without the anchor shown in
The methods described above to place the splint assemblies with respect to the heart can be repeated for any desired number of splint assemblies to achieve a particular configuration. The length of the tension members extending between the free wall and septal wall anchors also can be optimally determined based upon the size and condition of the patient's heart. It should also be noted that although the left ventricle has been referred to here for illustrative purposes, the apparatus and methods of this invention can be used to splint multiple chambers of a patient's heart, including the right ventricle or either atrium, or can be used to aid the function of valves, such as the mitral valve. An example of a preferred position of a splint assembly 1000 improves mitral valve function, as well as reducing stress in the left ventricular walls. The valve function is improved by aiding in the apposition of valve leaftlets when positioned as shown in
Furthermore, the alignments of the splints with respect to the heart that are described above are illustrative only and may be shifted or rotated about a vertical axis generally disposed through the left ventricle and still avoid the major coronay vessels and papillary muscles. In addition, the inventive devices and methods can be implanted to treat a heart having aneurysms or infarcted regions similar to those described in prior U.S. application Ser. No. 09/422,328 discussed earlier herein and incorported above.
The various components of the splint assembly to be implanted in the heart should be made of biocompatible material that can remain in the human body indefinitely. Any surface engaging portions of the heart should be atraumatic in order to avoid tissue damage and preferably formed of a material promoting tissue ingrowth to stabilize the anchor pad with respect to the surfaces of the heart.
It will be understood that this disclosure, in many respects, is only illustrative. Changes may be made in details, particularly in matters of shape, size, material, number and arrangement of parts without exceeding the scope of the invention. Accordingly, the scope of the invention is as defined in the language of the appended claims.
Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
Claims
1-56. (canceled)
57. A system for remodeling a mitral valve annulus, comprising:
- a delivery catheter;
- an implant, detachably carried by the delivery catheter, the implant reversibly movable between a first, flexible configuration for delivery to a site adjacent the annulus of the mitral valve and a second, rigid configuration for remodeling the mitral valve annulus;
- an elongate flexible control line having a first end attached to the implant and a second end spaced apart from the implant; and
- a coupling on the second end for releasable coupling to an adjustment tool.
58. A system as in claim 57, wherein the implant comprises an arc when in the remodeling configuration.
59. A system as in claim 58, wherein the implant comprises a compound curve when in the remodeling configuration.
60. A system as in claim 59, wherein the compound curve comprises a “w” configuration.
61. A system as in claim 57, further comprising a coating on the implant.
62. A system as in claim 57, further comprising an anchor for retaining the implant at a deployment site.
63. A system as in claim 62, wherein the anchor comprises a distal extension of the implant.
64. A system as in claim 62, wherein the anchor comprises a friction enhancing surface structure for engaging adjacent tissue.
65. A system as in claim 57, wherein the implant is adjustable in response to rotation of the control line.
66. A system as in claim 57, wherein the implant is adjustable in response to axial movement of the control line.
67. A method of treating a patient, comprising the steps of:
- identifying a patient having a control line connected to an implant residing within the patient;
- accessing the control line at a site on the patient that is remote from the implant; and
- manipulating the control line to adjust extravascular pressure exerted by the implant.
68. A method of treating a patient as in claim 67, wherein the identifying step comprises identifying a patient having an intravascular implant.
69. A method of treating a patient as in claim 67, wherein the manipulating step changes pressure exerted by the implant on the mitral valve.
70. A method of treating a patient, comprising the steps of:
- locating a control line positioned subcutaneously on the patient;
- exposing a portion of the control line; and
- manipulating the control line to mechanically change the hemodynamic function of a heart valve.
71. A method of treating a patient as in claim 70, wherein the manipulating step comprises connecting an adjustment tool to the control line and using the adjustment tool to manipulate the control line.
72. A method of providing a therapeutic compressive force against a tissue structure which is adjacent an implant, comprising the steps of positioning a device at a target site in a patient; the device connected by an elongate, flexible control line to a remote connector; coupling an adjustment tool to the connector; and actuating the adjustment tool to cause a portion of the device to move, thereby exerting a force against the adjacent tissue structure.
73. A method as in claim 72, wherein the positioning step is accomplished translumenally.
74. A method as in claim 72, wherein the positioning step is accomplished through an artificial tissue tract.
75. A method as in claim 72, wherein the positioning step is accomplished percutaneously.
76. A method as in claim 72, wherein the tissue structure comprises the mitral valve annulus.
77. A method as in claim 72, wherein the tissue structure comprises the left ventricle.
78. A method as in claim 76, wherein the positioning step comprises advancing the device translumenally through a vein.
79. A method as in claim 78, wherein the positioning step comprises percutaneously accessing the venous system prior to the positioning step.
80. A method as in claim 79, wherein the accessing step is accomplished by accessing one of the internal jugular, subclavian and femoral veins.
81. A method as in claim 72, further comprising the step of measuring hemodynamic function following the actuating step.
Type: Application
Filed: Oct 6, 2006
Publication Date: Mar 8, 2007
Applicant:
Inventors: Robert Vidlund (Maplewood, MN), Marc Simmon (Becker, MN), Todd Mortier (Minneapolis, MN), Cyril Schweich (St. Paul, MN), Peter Keith (St. Paul, MN), Richard Schroeder (Fridley, MN), Jason Kalgreen (Plymouth, MN)
Application Number: 11/543,892
International Classification: A61B 17/08 (20060101);